ClinicalTrials.gg
RecruitingNCT06086366PCOVUpdated Feb 11, 2026

Presynaptic Imaging in Major Depressive Episodes After COVID-19

An observational study in Long COVID, Major Depressive Disorder and Major Depressive Episode, sponsored by Centre for Addiction and Mental Health. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Centre for Addiction and Mental Health · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
90
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada — 14 open to participants now, 17 under way, 3 of them phase 3. Post-Acute COVID-19 Syndrome · Canada.

Started
2023
with 7 others
Observational
7 of 40
3 open now
Primary completion
2028-09
later than 14 of 16 live
Registered
24th of 40
by date
Lead sponsor
2 of 40
Centre for Addiction and Mental Health

Among the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, this one is one of 8 that started in 2023, is one of 7 observational ones, reaches primary completion later than 14 of the 16 other live ones, and was the 24th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

14 of the 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Post-Acute COVID-19 Syndrome with a site in Canada, or all of them as a file.
02

Study summary

The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.

Read the detailed description

Participants will undergo two positron emission tomography (PET) scans, one [11C]DTBZ scan (for vesicular monoamine transporter 2 (VMAT2) and one [18F]SDM8 scan (for synaptic vesicle glycoprotein 2A (SV2A)), as well as one magnetic resonance imaging (MRI) scan.

The main question[s] it aims to answer are:

  1. The investigators will determine if VMAT2 binding potential (VMAT2 BPND) is reduced in ventral striatum and dorsal putamen in COVID-DNP.
  2. The investigators will determine if SV2A total distribution volume (SV2A VT) is reduced in ventral striatum and dorsal putamen in COVID-DNP
03

Conditions studied

  • Long COVID
  • Major Depressive Disorder
  • Major Depressive Episode

Keywords

  • PET
  • Long COVID
  • Major Depressive Disorder
  • Major Depressive Episode
  • Anhedonia
  • Dopamine Neuron Loss
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Recovered from mild to moderate COVID-19 respiratory symptoms with subsequent onset of COVID-DNP

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • New onset MDE within 3 months after mild or moderate COVID-19, with MDE verified by the research version SCID for DSM 5. See "Positive COVID-19 diagnosis" listed after inclusion/exclusion criteria for a description of how this is determined.
  • Age 18 to 75.
  • Good general physical health with no active medical conditions based on self-report (except migraine or PASC).

Exclusion criteria

Exclusion Criteria:

  • Use of antidepressants in the previous month (6 weeks for fluoxetine).
  • Use of stimulant medication affecting dopamine release in the previous month
  • Use of antipsychotics in the previous month
  • History of neurological disease (except migraine, and PASC) based on self-report
  • Use of medications or herbal products or natural health products with central nervous system effects in past 2 weeks based on self-report
  • Presence of cigarette smoking in the past two months, based on self-report
  • Lifetime diagnosis of severe Substance or Alcohol Use Disorder, or diagnosis of mild to moderate Substance or Alcohol Use Disorder in the past two years, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)
  • Use of recreational drugs, including marijuana, in the past two months, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)
  • Positive urine drug or cotinine screen at any timepoint during the study
  • History of psychotic symptoms secondary to schizophrenia, schizophreniform, bipolar disorder, or brief psychotic disorder prior to COVID-19, based on self-report and verified by the Research Version of Structured Clinical Interview for Diagnostic and Statistical Manual-5 (SCID-5-RV)
  • Currently pregnant, based on self-report or positive pregnancy test at any timepoint during the study, in females (in our PET Centre females up to 65 years of age are given a urine pregnancy test prior to every PET scan)
  • Breastfeeding (for females)
  • Current disorders of coagulation, blood or ongoing use of anticoagulant medication, based on self-report
  • Claustrophobia, based on self-report
  • Weight over 400lbs and height over 7ft (requirements for fitting in the scanners and hospital gowns)
  • Presence of metal implant, object or electrical devices that are for MRI, based on self-report
  • Severe allergic reaction to alcohol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
90 participants (estimated)
Patient registry
No

Groups and cohorts

  • COVID-DNP

    Participants that have recovered from mild or moderate COVID-19 respiratory symptoms and have a new onset major depressive episode (MDE).

    Other: [11C]DTBZ PET scan · Other: [18F]SDM8 PET scan · Other: MRI scan

  • Healthy Control

    Participants in good physical health, age- and sex-matched to Group 1 and 2 participants.

    Other: [11C]DTBZ PET scan · Other: [18F]SDM8 PET scan · Other: MRI scan

Interventions

  • Other[11C]DTBZ PET scan

    One \[11C\]DTBZ scan for vesicular monoamine transporter 2 (VMAT2)

  • Other[18F]SDM8 PET scan

    One \[18F\]SDM8 scan for synaptic vesicle glycoprotein 2A (SV2A)

  • OtherMRI scan

    One MRI scan

06

What researchers measure

Primary outcomes

  1. Vesicular Monoamine Transporter 2 Binding Potential (VAMT2 BPND)

    The investigators will determine if VMAT2 BPND is changed in ventral striatum and dorsal putamen in COVID-DNP.

    Time frame: within 3 to 4 weeks after initiation of screening

  2. Synaptic Vesicle Glycoprotein 2A Total Distribution Volume (SV2A VT)

    The investigators will determine if SV2A VT is changed in ventral striatum and dorsal putamen in COVID-DNP

    Time frame: within 3 to 4 weeks after initiation of screening

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for Sep 2028, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2023
First posted
Oct 17, 2023
StartActual
Aug 22, 2023
Primary completionEst.
Sep 10, 2028
CompletionEst.
Sep 10, 2028
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06086366
Responsible party
Jeff Meyer (Scientist and Head, Neurochemical Imaging Program in Mood and Anxiety Disorders, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health) — Principal investigator
First posted
Oct 17, 2023
Start date
Aug 22, 2023
Primary completion
Sep 10, 2028 (estimated)
Completion
Sep 10, 2028 (estimated)
Last update
Feb 11, 2026

Study contacts

Karida Liu
Contact
liuyuhan0830@gmail.com
416-535-8501 ext. 39674
Jeffrey Meyer
Contact
jeffrey.meyer@utoronto.ca
416-535-8501 ext. 34007
Jeffrey Meyer, M.D., PhD
principal investigator · Centre for Addiction and Mental Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion